Business, Healthcare

The Bristol Myers Squibb Foundation and National Medical Fellowships launch $100 million program to help increase diversity and inclusion in clinical trials

Initiative will train 250 new clinical investigators and work within communities to build capacity to serve underrepresented patient populations PRINCETON, N.J.–(BUSINESS WIRE)–The Bristol Myers Squibb Foundation and National Medical Fellowships today announced that they have entered into a partnership aimed at improving

Business, Healthcare

Bristol Myers Squibb showcases research advancing outcomes addressing hard-to-treat blood cancers and diseases across small molecule, biologic and cell therapies at ASH 2020

Results for our CD19-targeted CAR T cell therapy lisocabtagene maraleucel (liso-cel) in patients with heavily pretreated mantle cell lymphoma and relapsed/refractory chronic lymphocytic leukemia Data showcasing BCMA-targeted CAR T cell therapy idecabtagene vicleucel (ide-cel), including updated results from the Phase 1 CRB-401

Business, Healthcare

KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) demonstrated statistically significant improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) versus Sunitinib as first-line treatment for patients…

LENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus Sunitinib Results of Investigational Phase 3 KEYNOTE-581/CLEAR Trial (Study 307) to be Presented at Upcoming Medical Meeting KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK): KEYTRUDA®